AU755957B2 - Delivery of immunogenic molecules via HBsAg particles - Google Patents

Delivery of immunogenic molecules via HBsAg particles Download PDF

Info

Publication number
AU755957B2
AU755957B2 AU22973/99A AU2297399A AU755957B2 AU 755957 B2 AU755957 B2 AU 755957B2 AU 22973/99 A AU22973/99 A AU 22973/99A AU 2297399 A AU2297399 A AU 2297399A AU 755957 B2 AU755957 B2 AU 755957B2
Authority
AU
Australia
Prior art keywords
molecule
hbsag
composition
particle
immunostimulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU22973/99A
Other languages
English (en)
Other versions
AU2297399A (en
Inventor
Yechezkel Barenholz
Dvorah Diminsky
Jorg Reimann
Reinhold Schirmbeck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Publication of AU2297399A publication Critical patent/AU2297399A/en
Assigned to REIMANN, JORG, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM reassignment REIMANN, JORG Alteration of Name(s) of Applicant(s) under S113 Assignors: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM
Application granted granted Critical
Publication of AU755957B2 publication Critical patent/AU755957B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU22973/99A 1998-02-03 1999-01-29 Delivery of immunogenic molecules via HBsAg particles Ceased AU755957B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7347698P 1998-02-03 1998-02-03
US60/073476 1998-02-03
PCT/IL1999/000060 WO1999039736A2 (en) 1998-02-03 1999-01-29 DELIVERY OF IMMUNOGENIC MOLECULES VIA HBsAg PARTICLES

Publications (2)

Publication Number Publication Date
AU2297399A AU2297399A (en) 1999-08-23
AU755957B2 true AU755957B2 (en) 2003-01-02

Family

ID=22113916

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22973/99A Ceased AU755957B2 (en) 1998-02-03 1999-01-29 Delivery of immunogenic molecules via HBsAg particles

Country Status (9)

Country Link
EP (1) EP1053018B1 (enExample)
JP (1) JP4480267B2 (enExample)
AT (1) ATE300312T1 (enExample)
AU (1) AU755957B2 (enExample)
CA (1) CA2319599C (enExample)
DE (1) DE69926342T2 (enExample)
DK (1) DK1053018T3 (enExample)
ES (1) ES2242376T3 (enExample)
WO (1) WO1999039736A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ912000A0 (en) * 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
DE10106235A1 (de) * 2001-02-10 2002-08-22 Bosch Gmbh Robert Wischarm
KR20060015534A (ko) 2003-04-25 2006-02-17 더 펜 스테이트 리서치 파운데이션 성장 억제, 지질 유래된 생활성 화합물의 전신 전달을 위한방법 및 시스템
CU23405A1 (es) * 2003-10-20 2009-08-04 Ct Ingenieria Genetica Biotech Composiciones farmacéuticas para uso terapéutico
PL1802746T3 (pl) 2004-10-27 2011-10-31 Crucell Switzerland Ag Cząstki wirosomu zawierające antygeny wirusa grypy i wirusa zapalenia wątroby typu B
JP2009120532A (ja) * 2007-11-14 2009-06-04 Osaka Univ 糖及び糖鎖認識機構を利用する物質送達用及びバイオイメージング用バイオナノカプセル

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0326109A2 (en) * 1988-01-29 1989-08-02 New York Blood Center, Inc. Improved immunogens containing peptides with an attached hydrophobic tail for adsorption to hepatitis B virus surface antigen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001526688A (ja) * 1997-05-19 2001-12-18 メルク エンド カンパニー インコーポレーテッド オリゴヌクレオチドアジュバント

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0326109A2 (en) * 1988-01-29 1989-08-02 New York Blood Center, Inc. Improved immunogens containing peptides with an attached hydrophobic tail for adsorption to hepatitis B virus surface antigen

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SCHIRMBECK ET.AL BIOL CHEM 380(3), MARCH 99 P 285-291 *
SCHIRMBECK ET.AL J.VIROLOGY 69(10), 95,P5929-5934 *

Also Published As

Publication number Publication date
JP4480267B2 (ja) 2010-06-16
EP1053018B1 (en) 2005-07-27
WO1999039736A2 (en) 1999-08-12
DK1053018T3 (da) 2005-08-15
CA2319599A1 (en) 1999-08-12
ES2242376T3 (es) 2005-11-01
AU2297399A (en) 1999-08-23
WO1999039736A3 (en) 1999-09-23
DE69926342D1 (de) 2005-09-01
DE69926342T2 (de) 2006-01-12
ATE300312T1 (de) 2005-08-15
JP2002502828A (ja) 2002-01-29
CA2319599C (en) 2011-04-19
EP1053018A2 (en) 2000-11-22

Similar Documents

Publication Publication Date Title
Chikh et al. Liposomal delivery of CTL epitopes to dendritic cells
Bramwell et al. Particulate delivery systems for vaccines
Schirmbeck et al. Virus-like Particles Induce MHC Class I-Restricted T-Cell Responses: Lessons learned from the hepatitis B small surface antigen
JP4535211B2 (ja) コクリエート送達ビヒクル
US9486510B2 (en) Method to enhance an immune response of nucleic acid vaccination
Moser et al. Virosomal adjuvanted antigen delivery systems
Gamvrellis et al. Vaccines that facilitate antigen entry into dendritic cells
AU731705B2 (en) Liposomal influenza vaccine composition and method
US7083787B2 (en) Yeast-dendritic cell vaccines and uses thereof
Morein et al. Immunomodulation by iscoms, immune stimulating complexes
JP7311560B2 (ja) 酵母細胞壁粒子を用いたワクチン送達系
HU220295B (hu) Antigénkészítmények és ezek alkalmazása citotoxikus T-limfocita reakciók indukálására
Adamiak et al. Archaeosomes and gas vesicles as tools for vaccine development
US8277778B2 (en) Vaccine adjuvants
Choi et al. Topical DNA vaccination with DNA/Lipid based complex
CA2319599C (en) Delivery of immunogenic molecules via hbsag particles
TWI457145B (zh) 以被包封於微脂粒內之蒂卡琳素（ｓｔｉｃｈｏｌｙｓｉｎ）為基礎的疫苗組成物
JP4638880B2 (ja) アルキルホスファチジルコリン配合ワクチン組成物
Gregoriadis Liposomes as immunological adjuvants for peptide and protein antigens
US7029680B1 (en) Delivery of immunogenic molecules vis HBsAg particles
WO2007150054A2 (en) Immunogenic compositions having altered glycosylations
EP1797895A1 (en) An adjuvant system comprising virosomes and liposomes
O'Hagan Recent advances in immunological adjuvants: the development of particulate antigen delivery systems
N. Gupta et al. Colloidal carrier systems for transcutaneous immunization
HK1228756A1 (en) Vaccine delivery systems using yeast cell wall particles

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW

Free format text: THE FORMER OWNER WAS: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM

FGA Letters patent sealed or granted (standard patent)